NO20004104L - Preparater omfattende virus og fremgangsmater for konsentrering av viruspreparater - Google Patents

Preparater omfattende virus og fremgangsmater for konsentrering av viruspreparater

Info

Publication number
NO20004104L
NO20004104L NO20004104A NO20004104A NO20004104L NO 20004104 L NO20004104 L NO 20004104L NO 20004104 A NO20004104 A NO 20004104A NO 20004104 A NO20004104 A NO 20004104A NO 20004104 L NO20004104 L NO 20004104L
Authority
NO
Norway
Prior art keywords
preparations
viruses
methods
concentrating virus
concentrating
Prior art date
Application number
NO20004104A
Other languages
English (en)
Other versions
NO20004104D0 (no
Inventor
John Chu-Tay Tang
Andreas Frei
Henry K H Kwan
Varda E Sandweiss
Gary J Vellekamp
Pui-Ho Yuen
Jr Laureano L Bondoc
Iv Frederick William Porter
Peter M Ihnat
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20004104D0 publication Critical patent/NO20004104D0/no
Publication of NO20004104L publication Critical patent/NO20004104L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20004104A 1998-02-17 2000-08-16 Preparater omfattende virus og fremgangsmater for konsentrering av viruspreparater NO20004104L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2446298A 1998-02-17 1998-02-17
US7964398A 1998-05-15 1998-05-15
PCT/US1999/001873 WO1999041416A2 (en) 1998-02-17 1999-02-12 Compositions comprising viruses and methods for concentrating virus preparations

Publications (2)

Publication Number Publication Date
NO20004104D0 NO20004104D0 (no) 2000-08-16
NO20004104L true NO20004104L (no) 2000-10-17

Family

ID=26698472

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004104A NO20004104L (no) 1998-02-17 2000-08-16 Preparater omfattende virus og fremgangsmater for konsentrering av viruspreparater

Country Status (24)

Country Link
EP (4) EP1526174B1 (no)
JP (3) JP4358434B2 (no)
KR (5) KR100918187B1 (no)
CN (2) CN101164623B (no)
AR (3) AR020054A1 (no)
AT (3) ATE341614T1 (no)
AU (1) AU757976B2 (no)
BR (1) BR9908015A (no)
CA (2) CA2320419C (no)
CO (1) CO4820440A1 (no)
DE (3) DE69942708D1 (no)
DK (1) DK1054955T3 (no)
ES (2) ES2290613T3 (no)
HU (1) HU226015B1 (no)
ID (1) ID28298A (no)
IL (2) IL137510A0 (no)
MY (1) MY141641A (no)
NO (1) NO20004104L (no)
PE (1) PE20000265A1 (no)
PL (1) PL197747B1 (no)
PT (1) PT1054955E (no)
SK (1) SK11842000A3 (no)
TW (1) TWI232107B (no)
WO (1) WO1999041416A2 (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0968284B1 (en) 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
EP1133316B1 (en) * 1998-11-16 2009-01-21 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
EP2420247A1 (en) 2000-03-07 2012-02-22 Merck Sharp & Dohme Corp. Adenovirus formulations
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
WO2002047726A2 (en) * 2000-12-12 2002-06-20 Japan Tobacco Inc. Pharmaceutical composition containing an active with a hemolytic action and a surfactant
CA2469491A1 (en) 2001-12-12 2003-06-19 Kerrie Setiawan Composition for viral preservation
US20030153065A1 (en) * 2002-01-14 2003-08-14 Genvec, Inc. Composition and method for maintaining non-enveloped viral vectors
US20030232018A1 (en) * 2002-01-18 2003-12-18 Berlex Biosciences Stabilized formulations of adenovirus
CN1922308A (zh) 2004-02-23 2007-02-28 克鲁塞尔荷兰公司 病毒纯化方法
CN101080488A (zh) 2004-11-03 2007-11-28 因特罗根治疗公司 生产和纯化腺病毒载体的新方法
WO2006065827A2 (en) 2004-12-13 2006-06-22 Canji, Inc. Cell lines for production of replication-defective adenovirus
ATE412737T1 (de) 2005-04-11 2008-11-15 Crucell Holland Bv Virusreinigung mit ultrafiltration
CN1961961B (zh) * 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
EP1974044B1 (en) 2005-12-12 2011-01-26 CANJI, Inc. Adenoviral expression vectors having an expression cassette in the e1 region and an inactivated e2b polymerase
PL2007883T3 (pl) * 2006-04-20 2012-07-31 Wyeth Llc Sposób oczyszczania do izolacji oczyszczonego wirusa pęcherzykowatego zapalenia jamy ustnej z hodowli komórkowej
EA019928B1 (ru) 2008-11-03 2014-07-30 Круселл Холланд Б.В. Способ получения аденовирусных векторов
SI3988660T1 (sl) 2009-05-02 2025-09-30 Genzyme Corporation Genska terapija za nevrodegenerativne motnje
PL2536829T3 (pl) 2010-02-15 2016-09-30 Sposób wytwarzania wektorów adenowirusowych Ad26
CA2808556A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
BR112013004582A2 (pt) 2010-09-27 2016-09-06 Crucell Holland Bv método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
CA2819236A1 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Lyophilized viral formulations
MX373096B (es) 2010-12-02 2020-04-27 Oncolytics Biotech Inc Formulaciones virales líquidas.
EA201391605A1 (ru) * 2011-04-29 2014-02-28 Онколитикс Байотек Инк. Способы очистки вирусов с использованием гельпроникающей хроматографии
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
KR102044051B1 (ko) 2012-03-12 2019-11-12 얀센 백신스 앤드 프리벤션 비.브이. 터미널 말단이 변경된 재조합 아데노바이러스의 배치
JP5845376B2 (ja) 2012-03-22 2016-01-20 クルセル ホランド ベー ヴェー Rsvに対するワクチン
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
PT2988780T (pt) 2013-04-25 2019-03-25 Janssen Vaccines & Prevention Bv Polipeptídeos f de pré-fusão do rsv solúveis estabilizados
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
SG11201609908VA (en) * 2014-05-28 2016-12-29 Agency Science Tech & Res Virus reduction method
AU2016249798B2 (en) 2015-04-14 2022-05-26 Janssen Vaccines And Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
AU2016289496B2 (en) 2015-07-07 2021-02-04 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
CN107847580B (zh) 2015-07-07 2022-08-12 扬森疫苗与预防公司 针对rsv的疫苗
AU2017248018A1 (en) 2016-04-05 2018-09-27 Janssen Vaccines & Prevention B.V. Vaccine against RSV
MX2018012094A (es) 2016-04-05 2019-01-10 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas.
SG11201810078PA (en) 2016-05-30 2018-12-28 Janssen Vaccines & Prevention Bv Stabilized pre-fusion rsv f proteins
US11001858B2 (en) 2016-06-20 2021-05-11 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2019021305A1 (en) * 2017-07-24 2019-01-31 Ella Foundation VACCINE AGAINST FOOT AND MOUTH DISEASE
AU2018333566A1 (en) 2017-09-15 2020-02-27 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
PE20211469A1 (es) 2018-11-13 2021-08-05 Janssen Vaccines And Prevention B V Proteinas f de prefusion del vrs estabilizadas
US20220267796A1 (en) * 2019-06-28 2022-08-25 Takeda Pharmaceutical Company Limited Adeno-associated virus purification methods
TW202204380A (zh) 2020-01-31 2022-02-01 美商詹森藥物公司 用於預防及治療冠狀病毒感染之組合物及方法-sars-cov-2疫苗
CN115484985A (zh) * 2020-03-19 2022-12-16 崔泽尔有限公司 温度响应病毒储存系统
US20240228548A9 (en) 2021-02-19 2024-07-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023020556A1 (zh) * 2021-08-17 2023-02-23 上海行深生物科技有限公司 病毒制剂、用于配制病毒制剂的溶液及其用途
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE299213C (no) *
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
GB1575155A (en) * 1978-04-11 1980-09-17 Merck & Co Inc Vaccine stabilizer
BE866330A (fr) * 1978-04-25 1978-10-25 Merck & Co Inc Procede de fabrication d'un agent de stabilisation de vaccin
US5532220A (en) 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
DD295927A5 (de) * 1988-05-06 1991-11-14 Saechsisches Serumwerk Gmbh Dresden, Immobilisiertes immunologisch aktives reagens
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
KR100368686B1 (ko) * 1994-12-29 2003-12-01 주식회사 엘지생명과학 수크로즈를이용한세포와바이러스의분리방법
FR2742756B1 (fr) * 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems

Also Published As

Publication number Publication date
KR20080065615A (ko) 2008-07-14
JP2002503484A (ja) 2002-02-05
AR063315A2 (es) 2009-01-21
EP1054955A2 (en) 2000-11-29
EP1741777A1 (en) 2007-01-10
AR063314A2 (es) 2009-01-21
CN100374551C (zh) 2008-03-12
CA2320419C (en) 2011-02-08
KR100862169B1 (ko) 2008-10-09
MY141641A (en) 2010-05-31
HUP0100670A3 (en) 2003-10-28
IL137510A (en) 2012-10-31
KR20090127947A (ko) 2009-12-14
JP4358434B2 (ja) 2009-11-04
DE69933433D1 (de) 2006-11-16
ES2272053T3 (es) 2007-04-16
JP2006166925A (ja) 2006-06-29
EP1526173B1 (en) 2012-11-21
AR020054A1 (es) 2002-04-10
PE20000265A1 (es) 2000-04-25
NO20004104D0 (no) 2000-08-16
AU2653899A (en) 1999-08-30
CN101164623A (zh) 2008-04-23
ATE478945T1 (de) 2010-09-15
DE69933433T2 (de) 2007-08-23
TWI232107B (en) 2005-05-11
ES2290613T3 (es) 2008-02-16
IL137510A0 (en) 2001-07-24
ID28298A (id) 2001-05-10
CN1297478A (zh) 2001-05-30
EP1741777B1 (en) 2010-08-25
PL342847A1 (en) 2001-07-16
PL197747B1 (pl) 2008-04-30
WO1999041416A2 (en) 1999-08-19
DE69936948D1 (de) 2007-10-04
WO1999041416A3 (en) 1999-11-18
EP1526174A2 (en) 2005-04-27
HU226015B1 (en) 2008-02-28
ATE341614T1 (de) 2006-10-15
CO4820440A1 (es) 1999-07-28
KR20090038927A (ko) 2009-04-21
BR9908015A (pt) 2001-04-24
EP1526174B1 (en) 2007-08-22
JP2010213727A (ja) 2010-09-30
KR100991683B1 (ko) 2010-11-04
SK11842000A3 (sk) 2001-05-10
HK1097413A1 (en) 2007-06-22
AU757976B2 (en) 2003-03-13
KR100918187B1 (ko) 2009-09-22
KR100912362B1 (ko) 2009-08-19
CA2723040A1 (en) 1999-08-19
HK1028416A1 (en) 2001-02-16
PT1054955E (pt) 2007-01-31
DE69936948T2 (de) 2008-05-15
DK1054955T3 (da) 2007-01-15
KR20080065614A (ko) 2008-07-14
EP1526173A3 (en) 2005-08-10
CN101164623B (zh) 2012-11-14
HUP0100670A2 (hu) 2001-06-28
DE69942708D1 (de) 2010-10-07
KR20010072547A (ko) 2001-07-31
EP1526173A2 (en) 2005-04-27
CA2320419A1 (en) 1999-08-19
KR101018992B1 (ko) 2011-03-07
EP1526174A3 (en) 2005-08-31
EP1054955B1 (en) 2006-10-04
HK1073481A1 (en) 2005-10-07
ATE371020T1 (de) 2007-09-15

Similar Documents

Publication Publication Date Title
NO20004104D0 (no) Preparater omfattende virus og fremgangsmÕter for konsentrering av viruspreparater
FI20080432L (fi) L-nukleosidejä hepatiitti-B-viruksen ja Epstein-Barr-viruksen hoitamiseksi
EP0859547A4 (en) VIRUS INACTIVE PACKAGING
NO991700D0 (no) Benzimidazol-2-karbamater for behandling av virusinfeksjoner og cancer
GB2337755B (en) Virus vaccine
PT773957E (pt) Polipeptidos truncados e1 e e2 de hepatite c inovadores, e metodos de obtencao dos mesmos
NO983965D0 (no) Polymer-organoleire-kompositter og deres fremstilling
DK1131301T3 (da) 2-phenylbenzimidazoler og 2-phenylindoler, fremstilling af anvendelse heraf
NO20005839D0 (no) Preparater for behandling av HIV og andre virale infeksjoner
DK0729956T3 (da) Benzothi9phenforbindelser, emllemprodukter, præparater og fremgangsmåder
NO20011162L (no) Fremgangsmåter og preparater for modulering av interaksjonen mellom APJ-reseptoren og HIV-viruset
FI963717L (fi) Uusia mutatoituja viruksia, viruksenvastaisia yhdisteitä ja uusia menetelmiä rokotteiden valmistamiseksi
FI955224L (fi) Hepatiitti-C-virustyypit 4,5 ja 6
EP1052988A4 (en) METHODS AND COMPILATIONS FOR INACTIVATING VIRUSES
NO971495L (no) Svekkede virus og fremgangsmåte til deres fremstilling
ATE270051T1 (de) Sossen- und suppenkonzentrat
DE60031826D1 (de) Trennung von Viren und Nachweis von Viren
NO991278L (no) FremgangsmÕte og system for sikker netthandel
NO983472D0 (no) Taxoider, deres fremstilling og farmas°ytiske preparater inneholdende taxoidene
IS5777A (is) Bóluefnisvakið lifrarbólgu B veiruafbrigði og notkun þess
EP0711310A4 (en) Human antibodies against varicella-zoster virus
NO20010464L (no) FremgangsmÕter og preparater for behandling av gastro- øsofagealt-reflukssyndrom
DK0826679T3 (da) Naphthylforbindelser og -præparater
DE69908495D1 (de) Sossen- und Suppenkonzentrat
AU4554899A (en) Novel hepatitis c virus peptides and uses thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application